{
  "ptid_time": "114_S_1118_2007-07-11",
  "img_path": "/data/qiuhui/data/adni/images/114_S_1118/2007-07-11/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 69,458 mm³, 47.7% above the reference mean. With a Z-score of 1.39 (91.7th percentile), this represents mild enlargement; hippocampal volume measures 5,295 mm³, 24.0% below the reference mean. With a Z-score of -2.07 (1.9th percentile), this represents significant atrophy; whole brain volume measures 891,788 mm³, 13.3% below the reference mean. With a Z-score of -1.75 (4.0th percentile), this represents moderate atrophy; entorhinal cortex volume measures 3,141 mm³, 20.9% below the reference mean. With a Z-score of -1.37 (8.6th percentile), this represents mild atrophy; fusiform gyrus volume measures 15,228 mm³, 15.7% below the reference mean. With a Z-score of -1.36 (8.7th percentile), this represents mild atrophy; middle temporal gyrus volume measures 17,317 mm³, 14.2% below the reference mean. With a Z-score of -1.27 (10.2th percentile), this represents mild atrophy. ",
  "text_data": "Age is 83.0 years. Gender is Male. Education: 12 years. MMSE: 28.0. APOEε4 alleles: 0.0. ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The imaging data shows significant hippocampal atrophy (Z-score -2.07, 1.9th percentile) and moderate whole-brain atrophy (Z-score -1.75, 4.0th percentile), which are strongly associated with Alzheimer's pathology. However, the MMSE score of 28 is within the normal range (≥26), and there is no APOE4 allele, which reduces genetic risk. The preserved cognitive performance despite structural changes suggests possible preclinical or very early-stage Alzheimer's.  \n\n**Diagnosis:** **MCI** (given the structural atrophy but intact cognition on MMSE, though this could also represent early dementia with atypical presentation)  \n**Confidence:** **Medium** (cognitive testing is borderline, and structural changes are significant but not yet clearly reflected in function)  \n\n*Note: A more sensitive cognitive assessment (e.g., MoCA, neuropsychological testing) or biomarkers (e.g., CSF Aβ/tau, PET) would help clarify.*",
  "timestamp": "2025-07-26T11:45:11.719484"
}